HC Wainwright Increases PepGen (NASDAQ:PEPG) Price Target to $20.00

PepGen (NASDAQ:PEPG) had its price objective hoisted by stock analysts at HC Wainwright from $18.00 to $20.00 in a research note issued on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price objective indicates a potential upside of 321.94% from the stock’s current price. HC Wainwright also issued estimates for PepGen’s Q1 2026 earnings at ($0.52) EPS, Q2 2026 earnings at ($0.52) EPS, Q3 2026 earnings at ($0.52) EPS and Q4 2026 earnings at ($0.52) EPS.

Other research analysts also recently issued reports about the company. Stifel Nicolaus boosted their target price on PepGen from $9.00 to $12.00 and gave the stock a “buy” rating in a report on Thursday, September 25th. Wedbush lifted their price objective on PepGen from $7.00 to $9.00 and gave the company an “outperform” rating in a research report on Thursday, September 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of PepGen in a research note on Wednesday, October 8th. Finally, Guggenheim restated a “buy” rating and issued a $6.00 target price on shares of PepGen in a research note on Wednesday, September 24th. Four analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, PepGen currently has an average rating of “Hold” and a consensus target price of $10.00.

PepGen Stock Performance

Shares of NASDAQ PEPG opened at $4.74 on Thursday. PepGen has a 52-week low of $0.88 and a 52-week high of $6.85. The business has a fifty day moving average of $4.00 and a two-hundred day moving average of $2.28. The stock has a market cap of $155.47 million, a PE ratio of -1.68 and a beta of 1.95.

PepGen (NASDAQ:PEPG) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.63) by $0.11. Analysts predict that PepGen will post -2.73 earnings per share for the current year.

Insider Activity

In other PepGen news, major shareholder Science Enterprises Plc Oxford purchased 200,000 shares of the stock in a transaction dated Tuesday, September 30th. The stock was bought at an average price of $3.20 per share, for a total transaction of $640,000.00. Following the transaction, the insider directly owned 4,955,388 shares in the company, valued at $15,857,241.60. This represents a 4.21% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 5.20% of the company’s stock.

Hedge Funds Weigh In On PepGen

Hedge funds and other institutional investors have recently bought and sold shares of the business. Burkehill Global Management LP acquired a new stake in PepGen during the 3rd quarter worth $46,000. XTX Topco Ltd bought a new position in shares of PepGen in the 1st quarter worth $25,000. ADAR1 Capital Management LLC acquired a new stake in shares of PepGen during the first quarter worth $29,000. Rangeley Capital LLC grew its stake in shares of PepGen by 133.3% during the second quarter. Rangeley Capital LLC now owns 35,000 shares of the company’s stock worth $39,000 after purchasing an additional 20,000 shares during the period. Finally, Marshall Wace LLP bought a new stake in PepGen in the second quarter valued at about $44,000. 58.01% of the stock is owned by institutional investors.

PepGen Company Profile

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.